PortViewPortView
Evogene logo

Evogene (EVGN) Stock Analysis

NASDAQHealthcareBiotechnology

$0.53+1.77%
1-year price historyRange $0.39 – $1.46
52-week range$0.53
$0.37$1.50

What Evogene does

Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.

Key metrics

Market cap
$4.57M
P/E (TTM)
-0.21
EPS (TTM)
$-2.58
Beta
0.78
Dividend yield
0.00%
Revenue / share
$0.11
50-day avg
$0.53
200-day avg
$0.80
52-week high
$1.50
52-week low
$0.37
CEO
Ofer Haviv

ETFs linked to EVGN

Broad-market and Healthcare sector ETFs an investor holding Evogene is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EVGN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze EVGN in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Evogene?
Evogene trades under the ticker EVGN on NASDAQ.
Which exchange is EVGN listed on?
EVGN is listed on NASDAQ.
What sector does Evogene operate in?
Evogene is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze EVGN in a portfolio?
PortView shows EVGN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.